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Abstract
Background: The receptor for advanced glycation end products (mRAGE) is associated with
pathology in most tissues, while its soluble form (sRAGE) acts as a decoy receptor. The adult lung
is unique in that it expresses high amounts of RAGE under normal conditions while other tissues
express low amounts normally and up-regulate RAGE during pathologic processes. We sought to
determine the regulation of the soluble and membrane isoforms of RAGE in the developing lung,
and its expression under hyperoxic conditions in the neonatal lung.
Results: Fetal (E19), term, 4 day, 8 day and adult rat lung protein and mRNA were analyzed, as
well as lungs from neonatal (0–24 hrs) 2 day and 8 day hyperoxic (95% O2) exposed animals.
mRAGE transcripts in the adult rat lung were 23% greater than in neonatal (0–24 hrs) lungs. On
the protein level, rat adult mRAGE expression was 2.2-fold higher relative to neonatal mRAGE
expression, and adult sRAGE protein expression was 2-fold higher compared to neonatal sRAGE.
Fetal, term, 4 day and 8 day old rats had a steady increase in both membrane and sRAGE protein
expression evaluated by Western Blot and immunohistochemistry. Newborn rats exposed to
chronic hyperoxia showed significantly decreased total RAGE expression compared to room air
controls.
Conclusion: Taken together, these data show that rat pulmonary RAGE expression increases
with age beginning from birth, and interestingly, this increase is counteracted under hyperoxic
conditions. These results support the emerging concept that RAGE plays a novel and homeostatic
role in lung physiology.
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Background
The receptor for advanced glycation end products
(mRAGE) belongs to the immunoglobulin superfamily
and binds a myriad of ligands such as advanced glycation
end products (AGEs)[1], amphoterin [2], and S100/cal-
granulin [3]. mRAGE has been implicated in the pathol-
ogy of various disorders, including diabetic
atherosclerosis, tumors and inflammation [4]. In contrast,
soluble RAGE (sRAGE) acts as a decoy receptor and in the
human is formed via alternative splicing [5], generating a
novel C-terminal sequence that lacks the mRAGE trans-
membrane domain. Heparin binding affinity of sRAGE
[6] may sustain its presence in the extracellular matrix, act-
ing as a buffer to halt detrimental ligand-mRAGE interac-
tions. mRAGE-ligand interaction has been associated, in
particular, with inflammation. In the lung, a recent study
has found there to be an increase in RAGE expression in
pulmonary pneumonias and smoke-related damage in
humans [7]. Notably, in non-pulmonary tissues, mRAGE-
ligand interactions have been shown to lead to an upreg-
ulation of the receptor [8].
Most tissues express low levels of mRAGE normally and
then up-regulate expression of this protein with injury
and disease. The lung is a notable exception to this pattern
with high levels of RAGE message [9] and protein [10] in
the normal adult lung. The high levels of RAGE expression
under normal conditions in the lung suggest there may be
a novel beneficial homeostatic role for this receptor in this
tissue [10].
The full extent of mRAGE and sRAGE expression in the
developing neonatal lung has not been examined.
mRAGE has been proposed as a marker of type I epithelial
cells, which differentiate during lung development [11].
Furthermore, Type II epithelial cells have also been shown
to express mRAGE mRNA [12]. The expression of RAGE
isoforms and glycosylation patterns in the developing
lung remains to be explored. Specifically, there are two
potential N-glycosylation sites in both mRAGE [13] and
sRAGE [6] that likely influence ligand-receptor affinity
[14]. We therefore sought to characterize the expression of
RAGE isoforms and their glycosylation patterns in the
developing rat lung.
The developing lung undergoes many changes at or near
parturition to facilitate the transition from a low fetal oxy-
gen tension to an increased postnatal tension [15]. The
etiologies of lung diseases in infants, such as bronchopul-
monary dysplasia (BPD), are poorly understood. How-
ever, the pathogenesis of BPD has been attributed in part
to the inflammation complicated by the requirement for
supplemental oxygen therapy, which lead to disrupted
alveolar development and damage in the lungs of prema-
ture infants [16]. Chronic hyperoxia in newborn rats is an
established model for the study of BPD and is associated
with increased lung inflammation, increased proteolytic
activity and edema [17], which have devastating conse-
quences to the developing lung. Inflammation and oxida-
tive stress can regulate mRAGE expression through
reactive oxygen species (ROS) formed as a result of TNF-
alpha stimulation in human umbilical vein endothelial
cells (HUVEC) [18]. The ability of sRAGE to scavenge det-
rimental ligands limits binding to mRAGE, and likely con-
fers a beneficial role. A loss of sRAGE or imbalance of
sRAGE/mRAGE may contribute to the pathology of BPD.
Therefore we sought to examine neonatal rats exposed to
hyperoxia to determine its effects on mRAGE and sRAGE
expression.
Results
To examine the developmental expression of RAGE and
its isoforms in the lung, mRAGE and sRAGE protein levels
were analyzed in rat neonatal (0–24 h) and adult lungs.
Western blot analysis revealed a 2-fold increase of mRAGE
expression in the adult lung compared to that seen in the
neonate (Fig. 1A). Western blot analysis of sRAGE
revealed a similar trend in which sRAGE expression was
significantly increased in the adult lung compared to the
neonatal lung (Fig. 1B). A representative Western blot
reveals a molecular weight variance between neonatal
sRAGE compared to adult sRAGE (Fig. 1C). This differ-
ence in size is likely due to a difference in glycosylation
(see below). Real-time RT-PCR amplification revealed a
23% increase in adult mRAGE mRNA compared to neona-
tal mRNA levels (Fig. 2) (p < 0.05).
To further investigate the increase in mRAGE and sRAGE
expression seen in development, additional time points
were tested. Fetal (E19), term, 4 day, 8 day and adult lungs
were collected and analyzed for both mRAGE and sRAGE
expression. Western blot analysis revealed a steady
increase in mRAGE and sRAGE expression (Fig. 3). Inter-
estingly, the fetal time point (E19) had only a single band
as opposed to all postnatal time points that showed bands
corresponding to both mRAGE and sRAGE, as well as pos-
sible additional glycosylation products of these respective
isoforms. Deglycosylation of neonatal and adult mRAGE
and sRAGE revealed homology in molecular weight, indi-
cating that alternative glycosylation is likely the cause for
the additional bands present in the neonatal samples (Fig.
4) and that the single fetal band was mRAGE.
Immunohistochemical examination of RAGE expression
in two, four, seven day and adult rat lungs reveals a grad-
ual rise in marked positive staining with increasing age
(Fig. 5). Receptor abundance was predominant in type I
pneumocytes.BMC Developmental Biology 2007, 7:15 http://www.biomedcentral.com/1471-213X/7/15
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To investigate how neonatal hyperoxia, an established
model of BPD, affects mRAGE expression, neonatal rats
(0–24 hrs) were exposed to 95% O2 for a period of two or
eight days. No significant difference in mRAGE or sRAGE
expression was evident after 2 days of hyperoxia (Fig. 6).
However, after chronic hyperoxia (8 days), sRAGE expres-
sion significantly decreased compared to room-air
exposed age-matched controls, while mRAGE levels
remained constant.
Discussions and Conclusion
mRAGE and sRAGE expression in normal lung develop-
ment and in response to hyperoxia were examined. Anal-
ysis of the developmental regulation of mRAGE and
sRAGE in the lung demonstrates that both neonatal rat
mRAGE and sRAGE expressions are lower than found in
adult lungs and there is an up-regulation of RAGE iso-
forms that occurs post-natally. In addition, extended
hyperoxic exposures result in a loss of sRAGE in the neo-
natal rat lung.
Several factors may account for the developmental up-reg-
ulation of RAGE in the lung. mRAGE has been identified
as a marker of type I epithelial cells [11], and the newborn
rat lung is not fully alveolarized. Therefore, the post-natal
increase in mRAGE in the neonatal rat lung may reflect
ongoing alveolarization characterized by an increase in
type I epithelial cells. Furthermore, RAGE expression may
be sensitive to oxygen tension [18]. The increase in RAGE
isoforms seen in the lung after birth may therefore also be
due, in part, to changes in oxygen tension occurring at
birth. While immunochemical examination of RAGE can
not distinguish between mRAGE and sRAGE due to the
inability of the antibody to distinguish these two iso-
forms, these immunohistochemical studies confirm that
the overall level of RAGE is up-regulated during develop-
Expression of mRAGE and sRAGE in neonatal and adult rat lung Figure 1
Expression of mRAGE and sRAGE in neonatal and adult rat lung. Western blot and subsequent densitometry was 
performed probing for mRAGE and sRAGE in lung homogenates. Results are normalized to β-actin. (A) Neonatal mRAGE 
expression compared to adult mRAGE (*p < 0.05). (B) sRAGE expression in adults compared to that seen in neonates (**p < 
0.01). (C) Representative Western blot showing sRAGE and mRAGE expression in the neonatal and adult lungs. Notably, a 
higher molecular weight band is seen in the neonatal soluble preps compared to the adult's and positive control. sRAGE seen 
in the adult and neonatal membrane preparations represents residual sRAGE remaining in pellet with insoluble proteins during 
sample preparation.
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ment (Fig. 5). This finding suggests that the increase in
RAGE expression does indeed correlate with alveolariza-
tion and the increase in type I cells.
A closer look at the soluble and membrane preparations
reveals a molecular weight variance between neonatal and
adult sRAGE. Interestingly term sRAGE contains a band
whose molecular weight does not match that of either the
adult sRAGE or neonatal mRAGE. We found that the
increase in molecular weight of the neonatal sRAGE is
likely due to different glycosylation patterns (see below).
To further assess the expression of mRAGE and sRAGE in
the developing lung, additional time-points were
explored. Fetal rat lungs express a single RAGE isoform
whose molecular weight appears to correspond to the
alternatively glycosylated mRAGE expressed in the neona-
tal lung. This corresponds to its expression in differentiat-
ing alveolar epithelial cells as reported previously by
Shirasawa et al. [11] and Katsuoka et al. [12]. Term, four
day and eight-day rat lungs demonstrated multiple RAGE
bands, which can correspond to different isoforms or gly-
cosylation patterns. It has been elucidated by Giron et
al[19] that multiple bands due to alternative splicing and
glycosylation patterns have been seen in the rat. There are
two possible N-glycosylation sites of RAGE. The two
sRAGE and mRAGE bands seen after N-glycosydase F
treatment reflect a partial deglycosylation (one sugar
removed) and complete deglycosylation (both removed).
Notably, when neonatal homogenates were deglyco-
sylated, their molecular weights aligned with that of the
adults to confirm that alternative glycosylation of the
mRAGE and sRAGE is likely responsible for the different
sizes of the RAGE bands seen between the early time-
points and older rats. Adult rat RAGE expression consists
of two distinct bands; the 50 kDa band of mRAGE and the
45 kDa band of sRAGE, consistent with observations in
mice [6]. We speculate that alternative glycosylation
present in neonates is either absent or present at undetec-
table levels in the normal adult lung. The alternative glyc-
osylation in the neonate may affect the affinity of the
receptor for its ligands. Previous studies looking at
amphoterin binding revealed a decrease in radio labeled
ligand-receptor binding with deglycosylation [14]. Fur-
ther work is required to evaluate the whether alternative
glycosylation in the neonate affects ligand binding.
Compared to adults, fetal and term lungs contain reduced
levels of the sRAGE isoform, which may lead to an
increased susceptibility to pathologic insults in the lung.
The fact that less sRAGE is present at this stage in develop-
ment to scavenge detrimental ligands may contribute to
the pathologic effects of mRAGE activation, which ulti-
mately leads to NF-kB activation [3]. Under hyperoxic
conditions it is known that NF-kB is activated in the
neonate but not in the adult [20]. The fact that the
mRAGE/sRAGE balance is skewed in neonatal lungs may
contribute to this difference in response between adult
and neonatal lungs. Alternatively, it has recently been
shown that mRAGE may be important in spreading of epi-
thelial cells and that sRAGE can inhibit this epithelial
spreading [21]. Thus, the absence of sRAGE at this early
time point may promote epithelial spreading of type I
cells during alveolar development.
In addition to examining RAGE expression during normal
lung development, this study also characterized the effects
of hyperoxia on mRAGE and sRAGE expression. One
main component of hyperoxic pulmonary injury is
inflammation, which can be devastating to the developing
lung. Because mRAGE signaling can be highly pro-inflam-
matory [1] and mRAGE expression is up-regulated in
response to inflammation in other tissues, RAGE isoform
expression was examined in a hyperoxic setting. Recent
work has shown an increase in lung RAGE abundance in
pulmonary inflammation caused by smoke-related dam-
age, and various pneumonias; an increase in its ligands
has also been shown [7], suggesting a role for RAGE in a
novel inflammatory pathway in the lung. However, our
results do not show an up-regulation of mRAGE (as it
appears unchanged even after chronic hyperoxia), but
rather a loss of sRAGE in response to hyperoxic injury. The
loss of sRAGE may be due to dilution as a result of edema.
Notably, when bronchoalveolar lavage fluid (BALF) was
analyzed in an adult model of hyperoxia, sRAGE was
detectable by Western blot (not shown), while in normal
conditions sRAGE was undetectable in the BALF [10]. His-
RAGE mRNA quantified by real-time RT-PCR Figure 2
RAGE mRNA quantified by real-time RT-PCR. Rat 
lung RAGE mRNA was quantified by real time PCR amplifica-
tion. These studies show an increase in adult RAGE mRNA 
compared to neonates. Results are expressed as inversed 
crossing-thresholds (CT) normalized to β-actin n = 3 (*p < 
0.05).
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Developmental expression of mRAGE and sRAGE in the lung Figure 3
Developmental expression of mRAGE and sRAGE in the lung. Lung protein samples were prepared with buffer con-
taining detergent to include both membrane and soluble isoforms of RAGE. (A) Densitometry was performed normalizing to 
β-actin (n = 3). (*p < 0.05) (B) Representative Western blot of RAGE isoforms and corresponding β-actin of fetal (E19), term, 
4 day, 8 day and adult rat lungs.
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Deglycosylation of neonatal and adult sRAGE and mRAGE Figure 4
Deglycosylation of neonatal and adult sRAGE and mRAGE. Neonatal (0–24 hrs) and adult soluble and membrane rat 
lung preparations were treated with N-glycosidase F and compared to untreated controls. After deglycosylation neonatal 
sRAGE bands resolved to match that of the adult sRAGE and neonatal mRAGE matched that of adult mRAGE (n = 2). The two 
bands seen for both sRAGE and mRAGE reveals a partial and complete deglycosylation.
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Immunochemical examination of RAGE expression in lung development Figure 5
Immunochemical examination of RAGE expression in lung development. Two, four, seven day and adult rat lungs 
were stained for RAGE followed by a hematoxylin counter stain. A gradual increase in positive staining was seen in the alveolar 
parenchyma with post-natal lung development, with marked staining in type I pneumocytes in the adult.
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tological examination would be difficult to establish a dif-
ference between control and test animals after O2
treatment as there is no change in mRAGE and a loss of
sRAGE; RAGE antibody detects the variable N-terminal
chain of the receptor making it isoform non-specific.
However, the Western blot data shows a significant loss of
sRAGE, indicating that after hyperoxia, an imbalance in
the ratio of sRAGE/mRAGE occurs that may contribute to
the pulmonary inflammation seen in a neonatal model of
BPD.
The expression of mRAGE in the lung before and after par-
turition and its subsequent elevated expression in the
adult lung, relative to other tissues, support the hypothe-
sis that this protein may play a homeostatic physiological
role in this tissue. These experiments have further shown
that sRAGE appears to be absent before birth which may
help promote type I cell spreading during alveolar devel-
opment. In addition, sRAGE is found to decrease in
response to hyperoxic injury which may promote mRAGE
signaling and contribute to further injury in this patho-
logic condition.
Methods
Lung tissue membrane and soluble homogenates
Adult (Pelfreeze) and neonatal (0–24 hrs following partu-
rition) rat lungs were weighed and homogenized in buffer
A [50 mM potassium phosphate pH 7.4, 0.3 M potassium
Effects of hyperoxic exposure on neonatal RAGE expression Figure 6
Effects of hyperoxic exposure on neonatal RAGE expression. Rat RAGE isoform expression was determined by West-
ern blot and densitometry was performed. Neonatal (0–24 hrs) rats were exposed either to 2 or 8 days of hyperoxia (95% 
O2) and compared to age matched room air controls (n = 3). Notably a decrease in sRAGE expression is seen after 8 days of 
hyperoxia (n = 3). (*p < 0.05)
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bromide, 3 mM diethylenetriamine pentaacetic acid, 0.5
mM phenylmethyl sulfonylfluride], sonicated, and centri-
fuged at 20,000 g for 20 minutes at 4°C. The supernatant
contained the soluble fraction to include sRAGE. The pel-
let was then resuspended in CHAPS detergent [22,23] vor-
texed, sonicated and shaken at 4°C for 2 hours. Following
incubation for 2 hrs at 4°C, samples were centrifuged at
20,000 g for 20 min at 4°C. This supernatant contained
the membrane fraction including RAGE. Western blot
analysis was performed as previously described [22-24].
RNA extraction and quantification
RNA was isolated from adult (Pelfreeze) and neonatal
whole lung using the Trizol (Invitrogen) method, as pre-
viously described (according to manufacturer's instruc-
tions) and analyzed using Light Cycler real-time reverse
transcription PCR with SYBR green conjugation
(Roche)[25]. Primers were generated for rat RAGE
(Sigma); sense primer 5'CTACCTATTCCTGCAGCTTC
and rat RAGE anti-sense primer 5'CTGATGTTGACAG-
GAGGGCTTTCC [19]. For normalization purposes, real-
time RT-PCR was performed for β-actin [26]. Cycling was
performed as previously described [10] and values
expressed as inversed crossing-threshold.
Lung tissue total protein homogenates
Lung tissue from fetal, term, four day, eight day and adult
rats was homogenized on ice in lysis buffer containing 50
mM Tris pH 7.6, 3% Igepal, 150 mM NaCl, 1 mM MgCl2,
and 5 mM EDTA. Lysis buffer also included 1:20 protease
inhibitors 1 mM 1, 10 phenanthroline, 2 mM 3,4 diiso-
coumarin, and 0.4 mM trans-epoxysuccinyl-L-leucyla-
mideo(4-guanidino)butane (E-64). Homogenates were
assayed for protein abundance and Western Blot per-
formed.
Immunohistochemistry of RAGE in the developing rat lung
Rat lung tissue was formalin fixed and paraffin embedded,
from which 5 micron sections were obtained. Antigen
retrieval was accomplished with a 40 min boil in Tris/
Urea buffer, (Tris-HCl, 5% urea, pH 6.0) and cooled for
20 minutes at room temperature (RT). Endogenous perox-
idase activity was blocked with 3% H2O2 for 10 minutes
at RT. Immunolabeling for RAGE was performed using a
rabbit anti-RAGE primary antibody (1:100) (Santa Cruz)
prepared in 1%BSA/PBS and detected using HRP conju-
gated secondary (BioGenex) followed by color develop-
ment in 3,3-diaminobenzidine (DAB) and counterstained
with hematoxylin as previously described [23].
Hyperoxic Exposures
Paired timed pregnant Sprague-Dawley rats (Charles River
Laboratories, Charles River, NJ) were obtained during late
gestation. Within 24 hours of delivery, the litters were
split evenly between two nursing dams and assigned ran-
domly to either air or 95% oxygen exposure for up to one
week. The dams were alternated every 24 hours between
the air and oxygen-exposed litters to prevent maternal
oxygen toxicity. After the exposure period, the rats were
euthanized with intraperitoneal pentobarbital (150 mg/
kg), lungs were perfused with 10 cc saline to remove
blood and lung tissue was flash-frozen in liquid nitrogen
and homogenized for total protein. All animal procedures
were approved by the Institutional Animal Care and Use
Committee [27,28].
Deglycosylation
Semi-purified RAGE and sRAGE were obtained by micro-
tube chromatography of 50 µg of protein from each sam-
ple utilizing Affi-Gel Heparin Gel (Bio-rad) to which
sRAGE is known to bind [6]. Samples were then concen-
trated using Microcon Citrifugal filter device (Millipore)
and centrifuged at 12,500 g for 20 min. Deglycosylation
of RAGE and sRAGE was performed on these concentrated
samples using N-Glycosidase F (2 µl for 100 U)(Calbio-
chem) as previously described [6]. Western blot analysis
was performed to determine glycosylation pattern, as pre-
viously described [10].
Statistical Analysis
Results were analyzed using a Student's-T test for paired
samples and one-way ANOVA followed by Tukey's multi-
ple comparison test to determine significance among a
group, values of p < 0.05 were deemed significant.
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